Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 2
1972 1
1973 2
1974 2
1975 2
1977 1
1978 5
1979 1
1982 1
1985 3
1986 3
1987 5
1988 2
1989 2
1990 2
1992 4
1993 1
1994 4
1995 1
1996 3
1997 3
1998 4
1999 4
2000 1
2001 4
2002 9
2003 1
2004 5
2005 2
2006 11
2007 3
2008 5
2009 13
2010 5
2011 4
2012 3
2013 6
2014 1
2015 3
2016 3
2017 2
2018 5
2019 6
2020 7
2021 7
2022 4
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

172 results

Results by year

Filters applied: . Clear all
Page 1
Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H, Fujita H, Ito K, Ochiiwa H, Fujioka Y, Ito K, Miura A, Sagara T, Ito S, Ohsawa H, Otsuki S, Funabashi K, Yashiro M, Matsuo K, Yonekura K, Hirai H. Sootome H, et al. Among authors: sagara t. Cancer Res. 2020 Nov 15;80(22):4986-4997. doi: 10.1158/0008-5472.CAN-19-2568. Epub 2020 Sep 24. Cancer Res. 2020. PMID: 32973082
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N. Goyal L, et al. Among authors: sagara t. Cancer Discov. 2019 Aug;9(8):1064-1079. doi: 10.1158/2159-8290.CD-19-0182. Epub 2019 May 20. Cancer Discov. 2019. PMID: 31109923 Free PMC article.
Redox of Viologen for Powering and Coloring.
Sagara T, Tahara H. Sagara T, et al. Chem Rec. 2021 Sep;21(9):2375-2388. doi: 10.1002/tcr.202100082. Epub 2021 May 25. Chem Rec. 2021. PMID: 34036724 Review.
Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use.
Ito S, Otsuki S, Ohsawa H, Hirano A, Kazuno H, Yamashita S, Egami K, Shibata Y, Yamamiya I, Yamashita F, Kodama Y, Funabashi K, Kazuno H, Komori T, Suzuki S, Sootome H, Hirai H, Sagara T. Ito S, et al. Among authors: sagara t. ACS Med Chem Lett. 2023 Mar 10;14(4):396-404. doi: 10.1021/acsmedchemlett.3c00006. eCollection 2023 Apr 13. ACS Med Chem Lett. 2023. PMID: 37077386 Free PMC article.
Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study.
Inatani M, Orii Y, Iwasaki K, Arimura S, Sunagawa H, Shiokawa M, Inoue K, Sakono T, Sakono T, Kuwamura R, Yoshida A, Oi J, Kuwayama Y, Kano K, Kido N, Matsuyama A, Ozaki M, Abe H, Inoue C, Nakagawa S, Musashi K, Kanamori A, Lee J, Otani S, Aoki R, Tanabe H, Nakakura S, Suzuki K, Sagara T, Saito Y, Sameshima M, Urahashi M, Watanabe-Kitamura F, Inoue T, Kagaya F, Murai Y, Mori S, Ueda K, Kurimoto T, Yamada-Nakanishi Y, Nakamura M, Yamashita T, Ishiyama S, Manabe S, Takaki K, Hayashi K, Ishida A, Tsutsui A, Manabe K, Tanito M. Inatani M, et al. Among authors: sagara t. Adv Ther. 2023 Sep;40(9):4074-4092. doi: 10.1007/s12325-023-02589-9. Epub 2023 Jul 15. Adv Ther. 2023. PMID: 37452961 Free PMC article. Clinical Trial.
Isolation of Three New Diterpenes from Dodonaea viscosa.
Sagara T, Sugimoto S, Yamano Y, Nehira T, Masuda K, Otsuka H, Matsunami K. Sagara T, et al. Chem Pharm Bull (Tokyo). 2021;69(1):40-47. doi: 10.1248/cpb.c20-00327. Chem Pharm Bull (Tokyo). 2021. PMID: 33390520 Free article.
Successful gene therapy requires targeting the vast majority of cancer cells.
Sagara T, Debeljak M, Wright CM, Anders NM, Liang H, Rudek MA, Ostermeier M, Eshleman JR, Matsushita Y. Sagara T, et al. Cancer Biol Ther. 2020 Oct 2;21(10):946-953. doi: 10.1080/15384047.2020.1809912. Epub 2020 Sep 30. Cancer Biol Ther. 2020. PMID: 32997949 Free PMC article.
172 results